潰瘍性大腸炎市場：疾患タイプ別（軽度UC、中等度UC、重度UC）、分子タイプ別（生物製剤、低分子製剤）、投与経路別（経口、注射剤）。世界の機会分析および産業予測、2020-2030年

Ulcerative Colitis Market By Disease Type (Mild UC, Moderate UC, Severe UC), By Molecule Type (Biologics, Small Molecules), By Route of Administration (Oral, Injectables): Global Opportunity Analysis and Industry Forecast, 2020-2030

潰瘍性大腸炎市場は、2020年には61億8029万ドル、2030年には107億6466万ドルに達し、2021年から2030年までCAGR5.7％で成長すると予測されています。潰瘍性大腸炎（UC）は、結腸または大腸を侵す炎症性消化器疾患... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年5月31日	US$5,398 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	225	英語

サマリー

潰瘍性大腸炎市場は、2020年には61億8029万ドル、2030年には107億6466万ドルに達し、2021年から2030年までCAGR5.7％で成長すると予測されています。潰瘍性大腸炎（UC）は、結腸または大腸を侵す炎症性消化器疾患です。UCは死亡率の低い難病として特徴づけられ、一般的に思春期から成人期初期に診断されます。
世界のUC市場の成長は、慢性炎症性腸疾患の憂慮すべき増加、医薬品産業発展のための政府の取り組み、UC製品の承認取得数の増加などが主な要因となっています。また、例えば、2021年6月、ファイザー株式会社は、中等度から重度の活動性UCを有する小児患者におけるトファシチニブの有効性、安全性および薬物動態を評価するための第III相臨床試験を開始しました。新製品の上市が市場の成長を後押ししています。さらに、Marc D Bassonが実施したUCに関する調査によると、2019年には約100万人がUCに罹患しています。さらに、Statistaによると、米国では約250万人が炎症性腸疾患に罹患していました。したがって、市場の成長を促進する要因は、炎症性腸疾患の発生率の増加と潰瘍性大腸炎治療薬の広範な使用です。
UCの管理に対する政府の支援の増加や効果的な治療に対する需要の急増は、世界のUC市場を牽引する主要な要因となっています。また、アボット・ラボラトリーズ、アストラゼネカ、エリ・リリーなどの主要企業がUCの治療薬を多数提供しており、市場の成長に寄与しています。
炎症性腸疾患の原因は、遺伝子、免疫系、環境要因の相互作用が関与していることが知られています。そのため、喫煙頻度の増加が炎症性腸疾患の原因となり、炎症性腸疾患市場の成長に寄与することが期待されています。
しかし、特許切れや代替手術の可能性が、市場の成長を制限しています。現在、人々は順番に、彼らの健康状態を維持し、潰瘍性大腸炎薬の治療のための需要を高めるためにそれらを強制的に、健康のより多くの意識を持っています。このため、多くの主要企業が新興国市場に参入し、潰瘍性大腸炎市場に有利な成長機会を提供しています。
潰瘍性大腸炎市場は、疾患タイプ、分子タイプ、投与経路、地域に基づいてセグメント化されています。疾患タイプ別では、軽度潰瘍性大腸炎、中等度潰瘍性大腸炎、重度潰瘍性大腸炎に分類されます。
分子タイプにより、低分子化合物と生物学的製剤に分類されます。また、投与経路によって、経口剤と注射剤に分けられます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。
世界の潰瘍性大腸炎市場で活動する主要企業には、アボット研究所、味の素、Astrazeneca Plc、Eli-Lilly、GlaxoSmithKline Plc、Index Pharmaceuticals Holdings AB、Johnson & Johnson、Merck & Co、Pfizer Inc、およびSanofiなどが含まれます。

ページTOPに戻る

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ULCERATIVE COLITIS MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Mild UC
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Moderate UC
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Severe UC
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Biologics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Small Molecules
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Injectables
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: ULCERATIVE COLITIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Molecule Type
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Molecule Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Molecule Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Molecule Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Molecule Type
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Molecule Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Molecule Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Molecule Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Molecule Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Molecule Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Molecule Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Molecule Type
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Molecule Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Molecule Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Molecule Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Molecule Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Molecule Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Molecule Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Molecule Type
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Molecule Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Molecule Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Molecule Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Molecule Type
7.5.5.4.3 Market size and forecast, by Route of Administration
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 AJINOMOTO CO. INC.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 ASTRAZENECA PLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 ELI-LILLY
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 INDEX PHARMACEUTICALS HOLDINGS AB
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 GLAXOSIMITHKLINE PLC
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 JOHNSON & JOHNSON
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Merck & Co. Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 SANOFI S.A
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030,($MILLION)
TABLE 2. ULCERATIVE COLITIS MARKET REVENUE, FOR MILD UC, BY REGION , 2020-2030,($MILLION)
TABLE 3. ULCERATIVE COLITIS MARKET MILD UC BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. ULCERATIVE COLITIS MARKET REVENUE, FOR MODERATE UC, BY REGION , 2020-2030,($MILLION)
TABLE 5. ULCERATIVE COLITIS MARKET MODERATE UC BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. ULCERATIVE COLITIS MARKET REVENUE, FOR SEVERE UC, BY REGION , 2020-2030,($MILLION)
TABLE 7. ULCERATIVE COLITIS MARKET SEVERE UC BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030,($MILLION)
TABLE 9. ULCERATIVE COLITIS MARKET REVENUE, FOR BIOLOGICS, BY REGION , 2020-2030,($MILLION)
TABLE 10. ULCERATIVE COLITIS MARKET BIOLOGICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. ULCERATIVE COLITIS MARKET REVENUE, FOR SMALL MOLECULES, BY REGION , 2020-2030,($MILLION)
TABLE 12. ULCERATIVE COLITIS MARKET SMALL MOLECULES BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
TABLE 14. ULCERATIVE COLITIS MARKET REVENUE, FOR ORAL, BY REGION , 2020-2030,($MILLION)
TABLE 15. ULCERATIVE COLITIS MARKET ORAL BY COUNTRY, 2020-2030,($MILLION)
TABLE 16. ULCERATIVE COLITIS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
TABLE 17. ULCERATIVE COLITIS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. ULCERATIVE COLITIS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 19. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030,($MILLION)
TABLE 20. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030,($MILLION)
TABLE 21. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
TABLE 22. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. U.S. ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 24. U.S. ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 25. U.S. ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 26. CANADA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 27. CANADA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 28. CANADA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 29. MEXICO ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 30. MEXICO ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 31. MEXICO ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 32. EUROPE ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030,($MILLION)
TABLE 33. EUROPE ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030,($MILLION)
TABLE 34. EUROPE ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
TABLE 35. EUROPE ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 36. GERMANY ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 37. GERMANY ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 38. GERMANY ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 39. FRANCE ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 40. FRANCE ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 41. FRANCE ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 42. U.K. ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 43. U.K. ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 44. U.K. ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 45. ITALY ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 46. ITALY ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 47. ITALY ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 48. SPAIN ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 49. SPAIN ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 50. SPAIN ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 51. REST OF EUROPE ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 52. REST OF EUROPE ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 53. REST OF EUROPE ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 54. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030,($MILLION)
TABLE 55. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030,($MILLION)
TABLE 56. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
TABLE 57. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 58. JAPAN ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 59. JAPAN ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 60. JAPAN ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 61. CHINA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 62. CHINA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 63. CHINA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 64. INDIA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 65. INDIA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 66. INDIA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 67. AUSTRALIA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 68. AUSTRALIA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 69. AUSTRALIA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 70. SOUTH KOREA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 71. SOUTH KOREA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 72. SOUTH KOREA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 73. REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 74. REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 75. REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 76. LAMEA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030,($MILLION)
TABLE 77. LAMEA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030,($MILLION)
TABLE 78. LAMEA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
TABLE 79. LAMEA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 80. BRAZIL ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 81. BRAZIL ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 82. BRAZIL ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 83. SAUDI ARABIA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 84. SAUDI ARABIA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 85. SAUDI ARABIA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 86. SOUTH AFRICA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 87. SOUTH AFRICA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 88. SOUTH AFRICA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 89. REST OF LAMEA ULCERATIVE COLITIS MARKET BY DISEASE TYPE 2020-2030,($MILLION)
TABLE 90. REST OF LAMEA ULCERATIVE COLITIS MARKET BY MOLECULE TYPE 2020-2030,($MILLION)
TABLE 91. REST OF LAMEA ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
TABLE 92.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 93.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 94.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 95.ABBOTT LABORATORIES: NET SALES,
TABLE 96.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 97.AJINOMOTO CO. INC.: COMPANY SNAPSHOT
TABLE 98.AJINOMOTO CO. INC.: OPERATING SEGMENTS
TABLE 99.AJINOMOTO CO. INC.: PRODUCT PORTFOLIO
TABLE 100.AJINOMOTO CO. INC.: NET SALES,
TABLE 101.AJINOMOTO CO. INC.: KEY STRATERGIES
TABLE 102.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 103.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 104.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 105.ASTRAZENECA PLC: NET SALES,
TABLE 106.ASTRAZENECA PLC: KEY STRATERGIES
TABLE 107.ELI-LILLY: COMPANY SNAPSHOT
TABLE 108.ELI-LILLY: OPERATING SEGMENTS
TABLE 109.ELI-LILLY: PRODUCT PORTFOLIO
TABLE 110.ELI-LILLY: NET SALES,
TABLE 111.ELI-LILLY: KEY STRATERGIES
TABLE 112.INDEX PHARMACEUTICALS HOLDINGS AB: COMPANY SNAPSHOT
TABLE 113.INDEX PHARMACEUTICALS HOLDINGS AB: OPERATING SEGMENTS
TABLE 114.INDEX PHARMACEUTICALS HOLDINGS AB: PRODUCT PORTFOLIO
TABLE 115.INDEX PHARMACEUTICALS HOLDINGS AB: NET SALES,
TABLE 116.INDEX PHARMACEUTICALS HOLDINGS AB: KEY STRATERGIES
TABLE 117.GLAXOSIMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 118.GLAXOSIMITHKLINE PLC: OPERATING SEGMENTS
TABLE 119.GLAXOSIMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 120.GLAXOSIMITHKLINE PLC: NET SALES,
TABLE 121.GLAXOSIMITHKLINE PLC: KEY STRATERGIES
TABLE 122.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 123.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 124.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 125.JOHNSON & JOHNSON: NET SALES,
TABLE 126.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 127.MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 128.MERCK & CO. INC.: OPERATING SEGMENTS
TABLE 129.MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 130.MERCK & CO. INC.: NET SALES,
TABLE 131.MERCK & CO. INC.: KEY STRATERGIES
TABLE 132.PFIZER INC.: COMPANY SNAPSHOT
TABLE 133.PFIZER INC.: OPERATING SEGMENTS
TABLE 134.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 135.PFIZER INC.: NET SALES,
TABLE 136.PFIZER INC.: KEY STRATERGIES
TABLE 137.SANOFI S.A: COMPANY SNAPSHOT
TABLE 138.SANOFI S.A: OPERATING SEGMENTS
TABLE 139.SANOFI S.A: PRODUCT PORTFOLIO
TABLE 140.SANOFI S.A: NET SALES,
TABLE 141.SANOFI S.A: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.ULCERATIVE COLITIS MARKET SEGMENTATION
FIGURE 2.ULCERATIVE COLITIS MARKET,2020-2030
FIGURE 3.ULCERATIVE COLITIS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ULCERATIVE COLITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.ULCERATIVE COLITIS MARKET,BY DISEASE TYPE,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF MILD UC ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MODERATE UC ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEVERE UC ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 15.ULCERATIVE COLITIS MARKET,BY MOLECULE TYPE,2020(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOLOGICS ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SMALL MOLECULES ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 18.ULCERATIVE COLITIS MARKET,BY ROUTE OF ADMINISTRATION,2020(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ORAL ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INJECTABLES ULCERATIVE COLITIS MARKET,2020-2030(%)
FIGURE 21.ULCERATIVE COLITIS MARKET BY REGION,2020
FIGURE 22.U.S. ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 23.CANADA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 24.MEXICO ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 25.GERMANY ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 26.FRANCE ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 27.U.K. ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 28.ITALY ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 29.SPAIN ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 30.REST OF EUROPE ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 31.JAPAN ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 32.CHINA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 33.INDIA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 34.AUSTRALIA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 35.SOUTH KOREA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 36.REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 37.BRAZIL ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 38.SAUDI ARABIA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 39.SOUTH AFRICA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 40.REST OF LAMEA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
FIGURE 48.AJINOMOTO CO. INC..: NET SALES ,($MILLION)
FIGURE 49.ASTRAZENECA PLC.: NET SALES ,($MILLION)
FIGURE 50.ELI-LILLY.: NET SALES ,($MILLION)
FIGURE 51.INDEX PHARMACEUTICALS HOLDINGS AB.: NET SALES ,($MILLION)
FIGURE 52.GLAXOSIMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 53.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 54.MERCK & CO. INC..: NET SALES ,($MILLION)
FIGURE 55.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 56.SANOFI S.A.: NET SALES ,($MILLION)

ページTOPに戻る

Table of Contents

Summary

The ulcerative colitis market was valued at $6,180.29 million in 2020, and is estimated to reach $10,764.66 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects the colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood.
Growth of the global UC market is majorly driven by alarming increase in number of chronic inflammatory bowel disease, rise in government initiatives for development of pharmaceutical industry, and increase in number of approvals for UC product. In addition, for instance, in June 2021, Pfizer Inc., initiated a phase III clinical trial to assess the efficacy, safety, and pharmacokinetics of tofacitinib in pediatric patients with moderately to severely active UC. The rise in new product launches drive the growth of the market. Moreover, according to the survey conducted by Marc D Basson on UC, in 2019, about one million people were affected with UC. Furthermore, as per Statista, around 2.5 million people were affected with inflammatory bowel disease in the U.S. Hence, the factors that drive the growth of the market are increase in incidences of inflammatory bowel disease and extensive uses of ulcerative colitis drugs.
Increase in government support for management of UC and surge in demand for effective treatment are the major factors that drive the global UC market. In addition, the key players such as Abbott Laboratories, Astrazeneca Plc., and Elli-Lilly provide numerous treatment products for UC, which contributes toward the market growth.
The cause of inflammatory bowel disease is known to involve an interaction between genes, the immune system, and environmental factors. Thus, increase in frequency of smoking causes the UC, which is expected to contribute towards the growth of UC market.
However, patent expiry and availability of alternative surgery option for UC treatment restrict the market growth. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for treatment of ulcerative colitis drugs. This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the ulcerative colitis market.
The ulcerative colitis market is segmented on the basis of disease type, molecule type, route of administration and region. By type, the market is categorized into mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis.
Depending on molecule type, it is divided into small molecules and biologics. As per route of administration, it is bifurcated into oral and injectable. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global ulcerative colitis market are Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（ネットワーク）の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD（ulcerative colitis）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

潰瘍性大腸炎市場：疾患タイプ別（軽度UC、中等度UC、重度UC）、分子タイプ別（生物製剤、低分子製剤）、投与経路別（経口、注射剤）。世界の機会分析および産業予測、2020-2030年

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（ネットワーク）の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD（ulcerative colitis）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?